Eisai Co., Ltd. ESAIY
7.86 USD -0.03 (-0.38%)
Nov 4, 2026, 10:37 AM EST
7.85 Day range 7.86
5.69 52-week range 8.58
- YTD
- +6.50%
- 1 year
- +7.52%
News
seekingalpha.com Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript
reuters.com FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver.
seekingalpha.com Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
seekingalpha.com Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
reuters.com Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday.
marketwatch.com These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated. A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
prnewswire.com Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting NUTLEY, N.J., April 9, 2026 /PRNewswire/ -- Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ)…
prnewswire.com Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline Additional filings are planned for the U.K., Canada and…
seekingalpha.com Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript
benzinga.com Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
seekingalpha.com Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions Transcript
prnewswire.com Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 TOKYO and CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,…
prnewswire.com Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase I b /II study TOKYO , Dec. 1, 2025 /PRNewswire/ -- Eisai…
seekingalpha.com Eisai Co., Ltd. (ESAIY) Q2 2026 Earnings Call Transcript Eisai Co., Ltd. (OTCPK:ESAIY) Q2 2026 Earnings Call November 5, 2025 1:30 AM EST Company Participants Haruo Naito - CEO, Representative Corporate Officer & Director Hideki Toyosaki Terushige Iike -…
reuters.com Merck, Eisai discontinue late-stage study for liver cancer therapy Merck and Japan's Eisai said on Wednesday they will shut down a late-stage study testing an experimental combination therapy to treat a type of liver cancer, after interim results showed the…
reuters.com Merck-Eisai's cancer drug combo meets one main goal in late-stage study Merck and Eisai's experimental combination treatment for a type of kidney cancer met one of the main goals in a late-stage study, the drugmakers said on Tuesday.
prnewswire.com Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an…
seekingalpha.com Eisai Co., Ltd. (ESAIY) Discusses On Latest Data On Lemborexant And Novel Orexin Receptor Agonist E2086 At The World Sleep 2025 Transcript Eisai Co., Ltd. (OTCPK:ESAIY) Disscusses on Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 Transcript Company Participants Katsutoshi Ido - VP, Chief…
prnewswire.com Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 TOKYO, Sept. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical…
prnewswire.com Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this…
reuters.com US FDA approves injectable version of Eisai-Biogen's Alzheimer's drug The U.S. Food and Drug Administration has approved an injectable version of Eisai and Biogen's Alzheimer's disease drug Leqembi, the companies said on Friday, allowing for an easier treatment option…